Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
0.86% $7.06
America/New_York / 17 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 299.48 mill |
EPS: | -1.480 |
P/E: | -4.77 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 42.42 mill |
Avg Daily Volume: | 0.138 mill |
RATING 2024-04-17 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Strong Buy | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -4.77 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.81x |
Company: PE -4.77 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.420 (-94.05%) $-6.64 |
Date: 2024-04-17 |
Expected Trading Range (DAY) |
---|
$ 6.70 - 7.40 ( +/- 4.91%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Hayes Christopher G. | Buy | 40 000 | Common Stock |
2024-03-15 | Hayes Christopher G. | Buy | 80 000 | Employee Stock Option (right to buy) |
2024-03-15 | Goldenberg Gary | Buy | 40 000 | Common Stock |
2024-03-15 | Goldenberg Gary | Buy | 80 000 | Employee Stock Option (right to buy) |
2024-03-15 | Kohler Terry | Buy | 80 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
91.16 |
Last 98 transactions |
Buy: 14 420 498 | Sell: 288 608 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $7.06 (0.86% ) |
Volume | 0.105 mill |
Avg. Vol. | 0.138 mill |
% of Avg. Vol | 75.76 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $5.20 | N/A | Active |
---|
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.